IL2 and systemic lupus erythematosus: He et al. demonstrated that low-dose recombinant human IL-2 selectively modulated the abundance of regulatory T (Treg) cells, follicular helper T (TFH) cells and IL-17-producing helper T (TH17) cells in patients with SLE (He et al. 2016).